HC Wainwright Has Bullish Outlook for LXEO FY2025 Earnings

Key Points

• HC Wainwright analyst M. Kapoor has raised Lexeo Therapeutics' FY2025 earnings per share estimate to ($2.21), up from a previous estimate of ($2.32), maintaining a "Buy" rating with a $13.00 price target.
• Lexeo Therapeutics recently reported Q2 earnings of ($0.60) per share, exceeding analysts’ expectations of ($0.64).
• Institutional investors now own 60.67% of Lexeo Therapeutics, with significant increases in holdings from firms like Frazier Life Sciences Management, which boosted its stake by 363.1%.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Analysts at HC Wainwright increased their FY2025 earnings per share estimates for Lexeo Therapeutics in a report issued on Tuesday, October 21st. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($2.21) per share for the year, up from their previous estimate of ($2.32). HC Wainwright has a "Buy" rating and a $13.00 price target on the stock. The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.14) per share. HC Wainwright also issued estimates for Lexeo Therapeutics' Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.37) EPS and FY2026 earnings at ($1.42) EPS.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.04.

Several other research firms also recently weighed in on LXEO. Oppenheimer started coverage on Lexeo Therapeutics in a research report on Thursday, July 31st. They set an "outperform" rating and a $20.00 price target for the company. Chardan Capital raised their price target on Lexeo Therapeutics from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Tuesday, October 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Lexeo Therapeutics in a research report on Wednesday, October 8th. Guggenheim started coverage on Lexeo Therapeutics in a research report on Wednesday, October 15th. They set a "buy" rating and a $30.00 price target for the company. Finally, Leerink Partners raised their price target on Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 7th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Lexeo Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $18.57.

Lexeo Therapeutics Stock Performance

Shares of LXEO stock opened at $9.23 on Thursday. The stock has a fifty day moving average price of $6.19 and a 200 day moving average price of $4.53. The stock has a market cap of $498.42 million, a PE ratio of -2.83 and a beta of 1.66. Lexeo Therapeutics has a 1 year low of $1.45 and a 1 year high of $11.72.

Insider Activity

In related news, CEO Richard Nolan Townsend sold 13,133 shares of Lexeo Therapeutics stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $117,409.02. Following the transaction, the chief executive officer owned 242,118 shares in the company, valued at approximately $2,164,534.92. This trade represents a 5.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tai Sandi See sold 3,888 shares of Lexeo Therapeutics stock in a transaction on Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $34,758.72. Following the completion of the transaction, the insider owned 65,862 shares in the company, valued at $588,806.28. The trade was a 5.57% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,091 shares of company stock valued at $232,007 over the last quarter. Company insiders own 5.30% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC boosted its holdings in Lexeo Therapeutics by 82.2% in the third quarter. CWM LLC now owns 18,864 shares of the company's stock valued at $125,000 after acquiring an additional 8,513 shares during the last quarter. Vestal Point Capital LP boosted its holdings in Lexeo Therapeutics by 184.1% in the second quarter. Vestal Point Capital LP now owns 3,228,161 shares of the company's stock valued at $12,977,000 after acquiring an additional 2,091,912 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in Lexeo Therapeutics by 363.1% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,424,725 shares of the company's stock valued at $17,787,000 after acquiring an additional 3,469,210 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Lexeo Therapeutics by 20.4% during the second quarter. BNP Paribas Financial Markets now owns 48,434 shares of the company's stock worth $195,000 after purchasing an additional 8,223 shares in the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in shares of Lexeo Therapeutics by 39.1% during the second quarter. Bridgeway Capital Management LLC now owns 53,400 shares of the company's stock worth $215,000 after purchasing an additional 15,000 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company's stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.